RGBP (Regen BioPharma) ROC (Joel Greenblatt) %: 0.00% (As of Mar. 2026)


What is Regen BioPharma ROC (Joel Greenblatt) %?

Regen BioPharma RGBP +100.00% ROC (Joel Greenblatt) % is 0.00% as of Mar. 2026. The stock has 7 warning signs investors should review. Among 1,325 Biotechnology companies, Regen BioPharma ranks worse than 75471.62% on this metric.

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Regen BioPharma's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 0.00%.

The historical rank and industry rank for Regen BioPharma's ROC (Joel Greenblatt) % or its related term are showing as below:

RGBP's ROC (Joel Greenblatt) % is not ranked *
in the Biotechnology industry.
Industry Median: -297.52
* Ranked among companies with meaningful ROC (Joel Greenblatt) % only.

Regen BioPharma's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.


Regen BioPharma  (OTCPK:RGBP) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


Regen BioPharma ROC (Joel Greenblatt) % Related Terms


Regen BioPharma ROC (Joel Greenblatt) % Historical Data

* Premium members only.

The historical data trend for Regen BioPharma's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Regen BioPharma ROC (Joel Greenblatt) % Chart

Regen BioPharma Annual Data
Trend Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
ROC (Joel Greenblatt) %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Regen BioPharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

RGBP vs SIGY, ENDV, CNBX: ROC (Joel Greenblatt) % Comparison

For the Biotechnology subindustry, Regen BioPharma's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Regen BioPharma ROC (Joel Greenblatt) % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Regen BioPharma's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Regen BioPharma's ROC (Joel Greenblatt) % falls into.



Regen BioPharma ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.232 + 0 + -2.7755575615629E-17) - (1.863 + 1.307 + 2.56)
=-5.498

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.26 + 0 + 0) - (2.006 + 1.275 + 1.379)
=-4.4

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of Regen BioPharma for the quarter that ended in Mar. 2026 can be restated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=4.112/( ( (0 + max(-5.498, 0)) + (0 + max(-4.4, 0)) )/ 1 )
=4.112/( ( 0 + 0 )/ 1 )
=4.112/0
= %

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROC (Joel Greenblatt) % of 0.00% mean?
Regen BioPharma (RGBP) has a ROC (Joel Greenblatt) % of 0.00% as of Mar. 2026. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Regen BioPharma and its competitors. According to the industry distribution chart, Regen BioPharma ranks #999999 out of 1325 companies in the Biotechnology industry.
Is Regen BioPharma's ROC (Joel Greenblatt) % too high?
Regen BioPharma's current ROC (Joel Greenblatt) % is 0.00%. Based on the distribution chart, Regen BioPharma ranks #999999 out of 1325 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Regen BioPharma's ROC (Joel Greenblatt) % compare to SIGY and ENDV?
According to the Biotechnology industry distribution chart, Regen BioPharma ranks #999999 out of 1325 companies for ROC (Joel Greenblatt) %. This places Regen BioPharma in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Biotechnology company?
A good ROC (Joel Greenblatt) % depends on the Biotechnology industry context. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Regen BioPharma and its competitors. Regen BioPharma's current ROC (Joel Greenblatt) % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Regen BioPharma stock overvalued right now?
Based on GuruFocus' analysis, Regen BioPharma (RGBP) is currently considered Possible Value Trap. The stock's GF Value™ is $0.02, compared to a current price of $0.00 — trading 99% below its estimated fair value. The current ROC (Joel Greenblatt) % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Regen BioPharma (RGBP), the current ROC (Joel Greenblatt) % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Regen BioPharma Business Description

Other Exchanges RGBPP.PFD:USA
Address 8697 La Mesa Boulevard, Suite C, La Mesa, CA, USA, 91942
Regen BioPharma Inc is a USA-based biotechnology company. It focuses on the development of regenerative medical applications in the stem cell space. The company's principal products and services include HemaXellarate I, HemaXellerate II, dCell Vax, NR2F6, Tcellvax, identification of Small Molecules, and others. HemaXellarate I and HemaXellerate II are cellular therapies designed to heal damaged bone marrow. dCell Vax is a therapy whereby dendritic cells of the cancer patient are harvested from the body. Tcellvax is an autologous cellular product comprised of NR2F6 gene-silenced peripheral blood mononuclear cells.